Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group, Peter W Horby, Guilherme Pessoa-Amorim, Leon Peto, Christopher E Brightling, Rahuldeb Sarkar, Koshy Thomas, Vandana Jeebun, Abdul Ashish, Redmond Tully, David Chadwick, Muhammad Sharafat, Richard Stewart, Banu Rudran, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Furst, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J Landray
doi: https://doi.org/10.1101/2021.02.11.21249258

Article Information

doi 
https://doi.org/10.1101/2021.02.11.21249258
History 
  • February 11, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. RECOVERY Collaborative Group*,
  2. Peter W Horby1,†,
  3. Guilherme Pessoa-Amorim2,
  4. Leon Peto2,
  5. Christopher E Brightling4,
  6. Rahuldeb Sarkar5,
  7. Koshy Thomas6,
  8. Vandana Jeebun7,
  9. Abdul Ashish8,
  10. Redmond Tully9,
  11. David Chadwick10,
  12. Muhammad Sharafat11,
  13. Richard Stewart12,
  14. Banu Rudran13,
  15. J Kenneth Baillie14,
  16. Maya H Buch15,
  17. Lucy C Chappell16,
  18. Jeremy N Day17,
  19. Saul N Furst18,
  20. Thomas Jaki19,
  21. Katie Jeffery20,
  22. Edmund Juszczak21,
  23. Wei Shen Lim22,
  24. Alan Montgomery21,
  25. Andrew Mumford23,
  26. Kathryn Rowan24,
  27. Guy Thwaites17,
  28. Marion Mafham2,
  29. Richard Haynes3 and
  30. Martin J Landray2,†
  1. 1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom;
  2. 2Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;
  3. 3MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;
  4. 4Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom;
  5. 5Medway Foundation NHS Trust, Gillingham, United Kingdom; King?s College London, London, United Kingdom;
  6. 6Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom;
  7. 7Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom;
  8. 8Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom;
  9. 9Royal Oldham Hospital, Northern Care Alliance, Oldham, United Kingdom;
  10. 10Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom;
  11. 11North West Anglia NHS Foundation Trust, Peterborough, United Kingdom;
  12. 12Milton Keynes University Hospital, Milton Keynes, United Kingdom;
  13. 13Luton & Dunstable University Hospital, Luton, United Kingdom;
  14. 14Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom;
  15. 15Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom;
  16. 16School of Life Sciences, Kings College London, London, United Kingdom;
  17. 17Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom;
  18. 18NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom;
  19. 19Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom;
  20. 20Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;
  21. 21School of Medicine, University of Nottingham, Nottingham, United Kingdom;
  22. 22Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom;
  23. 23School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom;
  24. 24Intensive Care National Audit and Research Centre, London, United Kingdom
  1. ↵†Correspondence to: Professor Peter W Horby and Professor Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom., Email: recoverytrial{at}ndph.ox.ac.uk
Back to top
Posted February 11, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, Peter W Horby, Guilherme Pessoa-Amorim, Leon Peto, Christopher E Brightling, Rahuldeb Sarkar, Koshy Thomas, Vandana Jeebun, Abdul Ashish, Redmond Tully, David Chadwick, Muhammad Sharafat, Richard Stewart, Banu Rudran, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Furst, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J Landray
medRxiv 2021.02.11.21249258; doi: https://doi.org/10.1101/2021.02.11.21249258
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area